DRUG · Unmapped registry intervention
HS-10296
Find medicine records ·
Find other trials using this name
Clinical trial
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
NCT03849768
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Gefitinib
Normalized identity: gefitinibView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non Small Cell Lung Cancerunresolved
Interventions
HS-10296DRUG
GefitinibDRUG · verified · RxNorm: gefitinib
Sponsors & collaborators
Jiangsu Hansoh Pharmaceutical Co., Ltd.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03849768 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.